Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2012

Piramal Reports Positive Data from Phase III Study with Chitosan Cartilage Repair Product

  • Piramal Healthcare presented positive data from a pivotal Phase III study evaluating its BST-CarGel® cartilage repair product, which achieved a European CE mark last month. The study demonstrated that BST-CarGel treatment was more effective than microfracture (the current standard of care) in terms of the degree of filling of treated lesions, and quality of new cartilage tissue. Treated cartilage was evaluated using a 3-D quantitative MRI technique that can compare both the quantity and quality of repaired cartilage structure.

    “The significant level of evidence from the BST-CarGel clincial trial, using multiple and independent methodologies, truly supports the positive effect of BST-CarGel over the standard of care on both the quantity and quality of regenerated cartilage tissue,” comments William Standish, M.D., principal trial investigator who is professor of surgery at Dalhousie University in Halifax, Nova Scotia. “This represents a cost-effective, off-the-shelf surgical alternative that may dramatically improve cartilage repair over traditional methods in a minimally invasive manner.”

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »